CLN8 Antilichaam - N-terminalgebied: FITC (ARP49408_P050-FITC)

Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)

EPMR, TLCD6, C8orf61

2055

Q9UBY8

NP_061764

Human, Mouse, Rat, Dog, Guinea Pig, Horse

The immunogen is a synthetic peptide directed towards the N terminal region of human CLN8

CLN8 is a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL) . Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain. Childhood-onset NCL are a group of autosomal recessive progressive encephalopathies characterized by the accumulation of autofluorescent material, mainly ATP synthase subunit C, in various tissues, notably in neurons. Based on clinical features, the country of origin of patients, and the molecular genetic background of the disorder, at least seven different forms are thought to exist. CLN8 is characterized by normal early development, onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation.This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL) . Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain.

YIPF6; ZUFSP; TMEM128; TMEM107; CYB5B; TMEM134; SELK; NDRG2; RTN4; RRP15; TMEM14A; GABARAPL2; C14orf1; ARL6IP5; TMEM147; TUBB4A; PDIA6; SPCS2; STX8; VAPA; TMEM11; UBC; PTPRN; PLP2; PLP1; MTX1; GPM6B; CD9; BNIP3L; BNIP3

FITC: Fluorescein Isothiocyanate

Polyclonal Antibody

WB

Affinity Purified

0.5 mg/ml

Dog: 100%; Guinea Pig: 86%; Horse: 100%; Human: 100%; Mouse: 100%; Rat: 82%

Liquid. Purified antibody supplied in 1x PBS buffer.

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.

33kDa

Hermansson, M., (2005) J. Neurochem. 95 (3), 609-617

Wet Ice

286

CLN8

CLN8

Rabbit

Protein CLN8

NM_018941

MNPASDGGTSESIFDLDYASWGIRSTLMVAGFVFYLGVFVVCHQLSSSLN